about
Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active statesHealth related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryCommon variable immunodeficiency-associated granulomatous and interstitial lung disease.Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis.Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activationPrognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly.Proteome analysis of bronchoalveolar lavage in pulmonary langerhans cell histiocytosisImmune response to Propionibacterium acnes in patients with sarcoidosis--in vivo and in vitro.Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular SarcoidosisCommon patterns and disease-related signatures in tuberculosis and sarcoidosisC-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal PneumoniaSarcoidosis--immunopathogenetic concepts.Essential role of osteopontin in smoking-related interstitial lung diseases.The Diagnosis, Differential Diagnosis, and Treatment of SarcoidosisNon-invasive biomarkers in pulmonary fibrosis.Immunologic response of sarcoidosis.The pathogenesis of pulmonary fibrosis: a moving target.Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases.Transcriptome profiles in sarcoidosis and their potential role in disease prediction.Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.[Sarcoidosis - Recent Advances].A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18.Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography.Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction.Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis.Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?Phenotyping sarcoidosis from a pulmonary perspective.
P50
Q28741912-7D8E4AC5-C2D4-4AE8-8326-84A8CDBAEA9FQ33908569-7A5D15F5-CA89-4FF6-AF29-B8FC3289375DQ34359481-86BBD5CA-E390-4864-AB4A-99BFC6DCF759Q34973462-1FEACEDC-0C16-45C8-8BE3-B13AD13F05E5Q35054029-7A96854F-70E6-4BE9-8A42-A33CB63D4388Q35593081-02B4DFFA-1A99-424B-BAF7-C7BAC17124DBQ35619235-CD719286-C0A0-4B3B-A710-9C8DF0EC3ABDQ35708762-077ACF34-C784-485D-8796-EED31AB62EC3Q35901288-5EB83405-C6F4-4153-974E-54DE10BFFFC3Q35974078-61B752A8-1025-408A-A5DA-47CFD639E567Q36214308-12083A77-5372-49E6-8D97-3D97865F60BAQ36748168-3F62DA5E-BA63-4C56-BF57-C80B4FA7861CQ37164171-42144009-7817-4FFD-BB1C-D1879926F892Q37241249-A06F2025-8215-46CF-B24A-DCA03040A940Q37585596-92E90853-5870-48E0-BF40-6483633A4FE7Q37776188-13F1F8AD-FDB5-436E-8366-F89DA8C7DF6EQ38055722-0DA03797-1E81-4495-A941-2B4C79EA56DFQ38735705-371CB74D-8EDF-46F8-917B-C64D48762E5AQ38738737-B1367CD4-0D84-4ABF-9E1B-8C6F598A040CQ39150142-E98D75B7-AF61-49BF-814D-75C0305BEA22Q39470428-0B146AD2-A4B5-4A02-B9EF-09740B68C32FQ40136175-35BB48C1-6FB0-48AC-92BB-D5ABBBB639D1Q40178788-E297E814-51BD-49C2-A570-21D8565298F9Q40328974-B73CAAD4-8513-4211-8159-71DA779A0F6BQ40657495-E324290E-8311-4F9A-8DAC-27461D296AF6Q42366226-753F14EE-1F1F-483B-AAB7-5F7C5EDD0B1CQ42464328-8E875FCF-F19A-4C46-8FAA-4EF706CC3CCCQ42950741-038F0BB0-80C8-4FF4-8138-BEF5D0FCBC2BQ45369141-3A8864D5-FA62-418D-A976-15976A849FB9Q46062356-F9395D12-F3B1-4DA6-9E0B-6DCE3414F3DFQ46920626-85EFB7AC-925F-433D-A461-597EF4BEC5A2
P50
name
Antje Prasse
@ast
Antje Prasse
@en
Antje Prasse
@es
Antje Prasse
@nl
type
label
Antje Prasse
@ast
Antje Prasse
@en
Antje Prasse
@es
Antje Prasse
@nl
prefLabel
Antje Prasse
@ast
Antje Prasse
@en
Antje Prasse
@es
Antje Prasse
@nl
P214
P21
P213
0000 0000 1839 8214
P214
P31
P7859
viaf-23077433